HOXA9 expression is also prominent in >50% of human AML cases [4–6], where it might contribute to myeloid transformation in part by reducing CEBPA expression and thereby interfering with myeloid differentiation. This evidence concerns the gene HOXA9 and acute myeloid leukemia.